(Total Views: 405)
Posted On: 03/04/2017 4:07:19 PM
Post# of 72441
Are you thinking about biOasis?
"Using biOasis’s Transcend Platform peptide carrier, MTfp, biOasis and researchers lead by Dr. Sean Lawler from the Department of Neurosurgery, Harvard Medical School, will work to deliver a number of compounds targeting glioblastoma tumors within the brain. The initial focus of the collaboration will be on the compounds, MTfp-TZM, MTfp-siRNA and MTfp-miRNA. The work will include moving the trastuzumab program forward towards human clinical trials."
http://www.bioasis.ca/2015/07/21/bioasis-tech...agreement/
"Using biOasis’s Transcend Platform peptide carrier, MTfp, biOasis and researchers lead by Dr. Sean Lawler from the Department of Neurosurgery, Harvard Medical School, will work to deliver a number of compounds targeting glioblastoma tumors within the brain. The initial focus of the collaboration will be on the compounds, MTfp-TZM, MTfp-siRNA and MTfp-miRNA. The work will include moving the trastuzumab program forward towards human clinical trials."
http://www.bioasis.ca/2015/07/21/bioasis-tech...agreement/
Quote:
Blood-brain barrier -- Can't remember what company it was that had developed a "carrier" molecule technology to help drugs do that -- but it's a big unknown to us about Kevetrin specifically.
(1)
(0)
Scroll down for more posts ▼
